Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	31/08/2015
Anders Waas BRD	Director/Board Member	69	31/12/2017
Carol Routledge BRD	Director/Board Member	-	31/12/2017

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+2.26%	+13.03%	-66.63%	-82.52%	8.42M
LONZA GROUP AG	+1.67%	+9.28%	-5.05%	+2.95%	45.45B
REVOLUTION MEDICINES, INC.	+4.72%	+7.98%	+358.19%	+607.64%	36.09B
BEONE MEDICINES AG	+1.42%	+3.44%	+4.61%	+55.16%	30.81B
IQVIA HOLDINGS INC.	+0.89%	+11.83%	+18.22%	-12.25%	30.98B
CELLTRION, INC.	+0.23%	-0.86%	+12.75%	+21.10%	24.62B
ASCENDIS PHARMA A/S	+9.37%	+11.37%	-	-	14.78B
MEDPACE HOLDINGS, INC.	+3.56%	+15.52%	+70.86%	+136.16%	14.65B
EUROFINS SCIENTIFIC SE	+1.88%	+8.59%	+13.76%	+21.62%	13.3B
IONIS PHARMACEUTICALS, INC.	+2.18%	+5.21%	+94.95%	+99.44%	12.65B
Average	+2.85%	+6.63%	+55.74%	+94.37%	22.33B
Weighted average by Cap.	+2.60%	+6.42%	+77.39%	+131.59%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
25/06/26	SEK 0.5420	+2.26%	1,308,817
24/06/26	SEK 0.5300	+8.72%	3,545,500
23/06/26	SEK 0.4875	-2.30%	207,925
22/06/26	SEK 0.4990	+4.07%	1,042,878
18/06/26	SEK 0.4795	-0.10%	235,407

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 16:21:32 25/06/2026 BST			5-day change	1st Jan Change
0.5420 ^SEK	+2.26%		+13.03%	-34.62%

Market Cap	82.13M 8.42M 7.41M 6.83M 6.39M 11.98M 793M 12.2M 31.81M 391M 31.6M 30.91M 1.36B	P/E 2026 *	-1.96x	P/E 2027 *	-1.39x
Enterprise Value	66.13M 6.78M 5.97M 5.5M 5.15M 9.64M 639M 9.82M 25.61M 315M 25.44M 24.89M 1.1B	EV / Sales 2026 *	2.11x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ

1 day	+2.26%
1 week	+13.03%
Current month	+25.90%
1 month	+12.92%
3 months	-7.98%
6 months	-32.25%
Current year	-34.62%

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.46	0.59
1 month	0.41	0.59
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.18
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.21M 2.83M 2.61M 2.44M 4.57M 303M 4.66M 12.14M 149M 12.06M 11.8M 520M	-
Net income	-3.2M -328K -289K -266K -249K -467K -30.91M -475K -1.24M -15.25M -1.23M -1.2M -53.05M	-50.35M -5.16M -4.54M -4.19M -3.92M -7.34M -486M -7.48M -19.5M -240M -19.37M -18.95M -835M
Net Debt	-16M -1.64M -1.44M -1.33M -1.25M -2.33M -155M -2.38M -6.2M -76.23M -6.16M -6.02M -265M	-19M -1.95M -1.71M -1.58M -1.48M -2.77M -184M -2.82M -7.36M -90.53M -7.31M -7.15M -315M